Essential (primary) hypertension. Essential (primary) hypertension
Conditions
Interventions
Intervention 1: Intervention group: recipient of routine drug treatment + Ziziphus jujuba fruit extract (7 g/day) for 4 weeks. Intervention 2: Intervention group: recipient of routine drug treatment +
Sponsors
Gorgan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: mmHg160 < blood pressure < mmHg 120 (Pre- and stage 1 hypertension) Voluntary participation in this clinical study and written consent
Exclusion criteria
Exclusion criteria: Other heart diseases Secondary hypertension Serum potassium> 5.5 mmol / L or <3.5mmol / L Doubling of serum creatinine in the last 6 months Severe complications of diabetes or seriousmacrovascular events within 6 months (e.g., cerebral hemorrhage, cerebral infarction, or acute myocardial infarction) Recent infection in the last 4 weeks Primary or secondary kidney disease (e.g., IgA nephropathy, membranous nephropathy, or lupus nephritis) Any cancer and malignancy Severe mental disorder Pregnant or lactating women or women who are planning to become pregnant or women who arenot using appropriate contraceptive methods Participate in other clinical trials Drug or jujube allergies Use of other herbal medicines to control the symptoms of the present disease History of smoking, drugs Other conditions that the researchers considered in appropriate in this clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypertension. Timepoint: Round 0: starting the study and receiving medication (face-to-face consultation)Round 1: 2 weeks after receiving the drug (telephone)The third round: the fourth week, the end of the medical treatment period (face-to-face consultation). Method of measurement: Mercury barometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in serum creatinine (SCr). Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood and urine tests.;EGFR. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood and urine tests.;Serum Albumin. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood and urine tests.;Lipid profiles. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood tests.;ECG. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Electrocardiograph.;Liver enzymes. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAref Salehi
Gorgan University of Medical Sciences
Outcome results
None listed